Skip to main content
. Author manuscript; available in PMC: 2015 Mar 7.
Published in final edited form as: BJU Int. 2014 Aug 13;114(0):E120–E129. doi: 10.1111/bju.12771

Fig. 1.

Fig. 1

Cancer-specific outcomes stratified by risk category. (A) Biochemical recurrence free survival. Proportion of patients free from biochemical recurrence at 10 years was 77% and 61%, for Pii and Pih patients respectively. In comparison, low, intermediate, and high risk patients had 10 year BFS of 91%, 68%, and 43%, respectively. P < 0.0001 for all comparisons. (B) Metastasis free survival. Proportion of patients free from metastasis at 10 years was 97% and 90%, for Pii and Pih patients respectively. In comparison, low, intermediate, and high risk patients had 10 year MFS of 99%, 92%, and 75%, respectively. P < 0.0001 for all comparisons. (C) Cancer-specific survival. Proportion of patients free from cancer-specific death at 10 years was 99% and 92%, for Pii and Pih patients respectively. In comparison, low, intermediate, and high risk patients had 10 year CSS of 99.5%, 96%, and 85%, respectively. P < 0.0001 for all comparisons.